Danish drugmaker Novo Nordisk is set to launch Ozempic (semaglutide) in India, a move that will benefit patients suffering from Type 2 Diabetes in the country, says India Head, Vikrant Shrotiya, in an exclusive conversation with India Today.

Ozempic is a once-a-week injectable brand that was originally approved to manage type 2 diabetes, but was seen as one of the most sought after drugs given its benefits in weight management.

Speaking to India Today, Shrotiya said, “With the highly anticipated launch expected soon, Novo Nordisk will now complete its semaglutide portfolio in India, providing a range of treatments to address diverse patient needs— oral semaglutide for diabetes, advanced obesity management through Injectable”

Ozempic was first approved by the US FDA in 2017. The company

See Full Page